Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Abstract

The relationship between whole brain radiotherapy (WBRT) dose with intracranial tumor control and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) is largely unknown. We retrospectively analyzed 595 NSCLC BM patients treated consecutively at the Fourth Hospital of Hebei Medical University between 2013 to 2015. We assigned the patients into 4 dose groups of WBRT: none, <\u200930, 30–39, and\u2009≥\u200940\u2009Gy and assessed their relationship with OS and intracranial progression-free survival (iPFS). Cox models were utilized. Covariates included sex, age, KPS, BM lesions, extracranial metastasis, BM and lung tumor resection, chemotherapy, targeted therapy, and focal radiotherapy modalities. Patients had a mean age of 59\u2009years and were 44% female. Their median survival time (MST) of OS and iPFS were 9.3 and 8.9\u2009months. Patients receiving none (344/58%), <\u200930 (30/5%), 30–39 (93/16%), and\u2009≥\u200940 (128/22%) Gy of WBRT had MST of OS (iPFS) of 7.3 (6.8), 6.0 (5.4), 10.3 (11.9) and 11.9 (11.9) months, respectively. Compared to none, other WBRT groups had adjusted HRs for OS - 1.23 (p\u2009>\u20090.20), 0.72 (0.08), 0.61 (<\u20090.00) and iPFS - 1.63 (0.03), 0.71 (0.06), 0.67 (<\u20090.01). Compared to 30–39\u2009Gy, WBRT dose ≥40\u2009Gy was not associated with improved OS and iPFS (all p\u2009>\u20090.40). Stratified analyses by 1–3 and\u2009≥\u20094 BM lesions and adjustment analyses by each prognostic index of RPA class, Lung-GPA and Lung-molGPA supported these relationships as well. Compared to none, WBRT doses ≥30\u2009Gy are invariably associated with improved intracranial tumor control and survival in NSCLC BM patients.